Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson launches generic oral contraceptive product
Watson Pharma, a subsidiary of Watson Pharmaceuticals, has begun shipment of the product. Vestura is indicated for the prevention of pregnancy and for the treatment of moderate acne
Watson Pharma, a subsidiary of Watson Pharmaceuticals, has begun shipment of the product. Vestura is indicated for the prevention of pregnancy and for the treatment of moderate acne
The new facility, which will more than double the current facility, is expected to get completed in 2012. The fill/finish suites will feature automated vial and syringe filling,
Fabrazyme (agalsidase beta) is used to treat patients with Fabry disease. Fabrazyme lowers the amount of a substance called globotriaosylceramide (GL-3), which builds up in cells lining the
The trial demonstrated that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters and reached its anticipated endpoints. IFX-1 was designed to control the
Aptalis Pharma and Gilead have co-developed the oral powder formulation of Viread using the Aptalis Microcaps taste-masking technology. The Aptalis microencapsulation technology, known as Microcaps, employs versatile and
Hylase Wound Gel is indicated for the management and treatment of leg ulcers, pressure ulcers, diabetic ulcers and exuding wounds prone to bleeding. ECR Pharmaceuticals, Hi-Tech’s branded subsidiary,
Lucentis is a humanized therapeutic antibody fragment designed to block all biologically active forms of vascular endothelial cell growth factor-A (VEGF-A). Lucentis has been formulated specifically for use
Ibudilast demonstrated significant efficacy in a model of post-TBI anxiety, one of the most common disorders caused by TBI. A short course of systemic ibudilast administered over a
The objectives of double-blinded, randomized trial, are to assess the efficacy, local tolerability and safety of DPK-060 ear drops in infections caused by bacterial or fungal pathogens. The
Sycrest is a sublingual tablet marketed as Sycrest in Europe, and as Saphris in other markets worldwide. Sycrest is an antipsychotic that differs structurally from currently available medications